Allianz Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$431M Sell
3,094,227
-936,303
-23% -$131M 0.45% 34
2025
Q4
$495M Sell
4,030,530
-1,742,489
-30% -$212M 0.5% 26
2025
Q3
$641M Sell
5,773,019
-451,098
-7% -$51.3M 0.72% 18
2025
Q2
$690M Buy
6,224,117
+438,200
+8% +$46.6M 0.83% 14
2025
Q1
$648M Buy
5,785,917
+676,824
+13% +$69.8M 0.85% 16
2024
Q4
$472M Buy
5,109,093
+783,538
+18% +$70.5M 0.63% 20
2024
Q3
$363M Buy
4,325,555
+107,066
+3% +$8.17M 0.51% 33
2024
Q2
$289M Sell
4,218,489
-95,091
-2% -$6.35M 0.43% 41
2024
Q1
$316M Buy
4,313,580
+89,105
+2% +$6.85M 0.49% 43
2023
Q4
$342M Buy
4,224,475
+248,618
+6% +$19.3M 0.56% 32
2023
Q3
$298M Buy
3,975,857
+237,498
+6% +$18.3M 0.5% 41
2023
Q2
$288M Buy
3,738,359
+564,888
+18% +$45.1M 0.52% 38
2023
Q1
$263M Buy
3,173,471
+138,997
+5% +$11.5M 0.47% 36
2022
Q4
$261M Sell
3,034,474
-649,647
-18% -$51.4M 0.51% 34
2022
Q3
$227M Sell
3,684,121
-295,680
-7% -$18.6M 0.46% 40
2022
Q2
$246M Sell
3,979,801
-51,620
-1% -$3.2M 0.23% 100
2022
Q1
$240M Sell
4,031,421
-147,695
-4% -$9.44M 0.18% 133
2021
Q4
$304M Sell
4,179,116
-205,749
-5% -$14.2M 0.21% 106
2021
Q3
$306M Buy
4,384,865
+3,242,180
+284% +$228M 0.24% 94
2021
Q2
$78.7M Sell
1,142,685
-312,188
-21% -$20.8M 0.07% 281
2021
Q1
$94M Buy
1,454,873
+143,830
+11% +$9.27M 0.09% 226
2020
Q4
$76.4M Buy
1,311,043
+222,317
+20% +$13.4M 0.08% 261
2020
Q3
$68.8M Sell
1,088,726
-1,518,823
-58% -$105M 0.08% 258
2020
Q2
$201M Sell
2,607,549
-844,813
-24% -$64.7M 0.23% 98
2020
Q1
$258M Sell
3,452,362
-191,630
-5% -$13.2M 0.35% 52
2019
Q4
$237M Sell
3,643,992
-44,395
-1% -$2.89M 0.22% 98
2019
Q3
$234M Sell
3,688,387
-671,394
-15% -$43.9M 0.23% 86
2019
Q2
$295M Sell
4,359,781
-201,207
-4% -$13.2M 0.27% 66
2019
Q1
$297M Sell
4,560,988
-222,895
-5% -$14.8M 0.29% 63
2018
Q4
$299M Buy
4,783,883
+249,140
+5% +$17.4M 0.33% 56
2018
Q3
$350M Buy
4,534,743
+605,846
+15% +$45.8M 0.32% 57
2018
Q2
$278M Sell
3,928,897
-448,179
-10% -$31.6M 0.27% 63
2018
Q1
$330M Sell
4,377,076
-733,168
-14% -$58.3M 0.31% 53
2017
Q4
$366M Buy
5,110,244
+597,615
+13% +$45.4M 0.29% 58
2017
Q3
$366M Buy
4,512,629
+466,059
+12% +$35.6M 0.32% 46
2017
Q2
$287M Buy
4,046,570
+420,400
+12% +$28M 0.28% 58
2017
Q1
$246M Sell
3,626,170
-1,054,219
-23% -$74.1M 0.24% 67
2016
Q4
$335M Buy
4,680,389
+338,408
+8% +$25.2M 0.3% 47
2016
Q3
$342M Sell
4,341,981
-2,792,872
-39% -$227M 0.33% 49
2016
Q2
$595M Buy
7,134,853
+262,429
+4% +$23.3M 0.63% 21
2016
Q1
$631M Buy
6,872,424
+154,047
+2% +$13.9M 0.72% 20
2015
Q4
$681M Buy
6,718,377
+250,282
+4% +$26M 0.77% 18
2015
Q3
$635M Buy
6,468,095
+232,147
+4% +$25.8M 0.76% 23
2015
Q2
$731M Buy
6,235,948
+2,471,418
+66% +$270M 0.78% 13
2015
Q1
$369M Sell
3,764,530
-784,536
-17% -$79.7M 0.42% 53
2014
Q4
$429M Sell
4,549,066
-391,845
-8% -$40.5M 0.48% 40
2014
Q3
$526M Sell
4,940,911
-48,505
-1% -$4.75M 0.63% 25
2014
Q2
$414M Sell
4,989,416
-258,041
-5% -$20.1M 0.52% 39
2014
Q1
$372M Buy
5,247,457
+282,645
+6% +$22.2M 0.45% 46
2013
Q4
$373M Buy
4,964,812
+718,702
+17% +$50M 0.48% 51
2013
Q3
$267M Buy
4,246,110
+1,020,941
+32% +$61M 0.35% 68
2013
Q2
$165M Buy
+3,225,169
New +$168M 0.23% 94

Other funds holding GILD

Allianz Asset Management's GILD Position: Q1 2026 in Review

Allianz Asset Management reduced its Gilead Sciences (GILD) stake by 23% in Q1 2026, selling an estimated $131M and leaving 3,094,227 shares worth $431M. The position accounts for 0.45% of the portfolio, ranked #34.

Allianz Asset Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $731M in Q2 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Allianz Asset Management held 3,094,227 shares of Gilead Sciences worth $431M as of Q1 2026.
  • Allianz Asset Management sold 936,303 Gilead Sciences shares in Q1 2026, an estimated $131M.
  • Gilead Sciences made up 0.45% of Allianz Asset Management's portfolio in Q1 2026, its #34 holding.
  • Allianz Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Allianz Asset Management's Gilead Sciences position peaked at $731M in Q2 2015.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.